Search

Displaying results 6821 - 6830 of 10000 in total
  1. Drug

    Lixivaptan

    go.drugbank.com/drugs/DB06666
    Investigational

  2. Drug

    PRX-03140

    go.drugbank.com/drugs/DB05596
    Investigational

  3. Drug

    Bedoradrine

    go.drugbank.com/drugs/DB05590
    Investigational

  4. Drug

    Aplindore

    go.drugbank.com/drugs/DB06620
    Investigational

  5. Drug

    Distigmine

    go.drugbank.com/drugs/DB13694
    Investigational

    Distigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide. … It improves detrusor function thereby restoring normal voiding patterns in patients suffering from detrusor underactivity [A27176].

  6. Drug

    Afimetoran

    go.drugbank.com/drugs/DB16580
    Investigational

    [L32018, L32023] It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male … Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8.

  7. Drug

    Reloxiliase

    go.drugbank.com/drugs/DB17653
    Experimental

    Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.[A258823]

  8. Drug

    WP-1301

    go.drugbank.com/drugs/DB17702
    Experimental

    WP1301 is a synthetic peptide derived from hFVIII. It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]

  9. Drug

    Agatolimod

    go.drugbank.com/drugs/DB15018
    Investigational

    Agatolimod is under investigation in clinical trial NCT00471471 (Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery).

  10. Drug

    Interferon alfa-2c

    go.drugbank.com/drugs/DB15131
    Investigational

    Interferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma).

    Categories: Interferon Type I